Sugi Predict

Sugi Predict / Compounds / SCHEMBL837824

SCHEMBL837824

SCHEMBL837824

C[C@H](Nc1cccc(C(F)(F)F)c1)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.70
▸ KDM4E B2RXH2 1/20 0.70
▸ TP53 P04637 2/20 0.57
▸ CA12 O43570 1/20 0.57
▸ CA1 P00915 1/20 0.57
▸ MMP2 P08253 1/20 0.57
▸ MAPT P10636 3/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ HTT P42858 1/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ ALDH1A1 P00352 4/20 0.51
▸ KIF11 P52732 1/20 0.51
▸ CYP1A2 P05177 2/20 0.51
▸ CYP3A4 P08684 2/20 0.51
▸ CYP2C9 P11712 2/20 0.51
▸ LMNA P02545 2/20 0.51
▸ GAA P10253 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29446980 1.00 SMN1; SMN2 (0.70) SMN1; SMN2KDM4ETP53CA12CA1
SCHEMBL18838552 1.00 SMN1; SMN2 (0.70) SMN1; SMN2KDM4ETP53CA12CA1
SCHEMBL963073 0.86 SMN1; SMN2 (0.57) SMN1; SMN2KDM4ETP53CA12CA1
SCHEMBL967255 0.86 SMN1; SMN2 (0.57) SMN1; SMN2KDM4ETP53CA12CA1
SCHEMBL11206192 0.85 NPSR1 (0.60) SMN1; SMN2KDM4ETP53CA12CA1
SCHEMBL11206190 0.85 NPSR1 (0.60) SMN1; SMN2KDM4ETP53CA12CA1
SCHEMBL2336933 0.84 SMN1; SMN2 (0.58) SMN1; SMN2KDM4ETP53CA12CA1
SCHEMBL2336931 0.84 SMN1; SMN2 (0.58) SMN1; SMN2KDM4ETP53CA12CA1
SCHEMBL6706715 0.83 KDM4E (0.52) SMN1; SMN2KDM4EMAPTALDH1A1LMNA
SCHEMBL6706711 0.83 KDM4E (0.52) SMN1; SMN2KDM4EMAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3374520-A1 BIOSENSORS Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2018-09-19 — — EP claimed
WO-2017081684-A1 BIOSENSORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2017-05-18 — — WO claimed
US-20190144924-A1 BIOSENSORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2019-05-16 — — US disclosed
EP-3374520-A1 BIOSENSORS Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2018-09-19 — — EP disclosed
WO-2017081684-A1 BIOSENSORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2017-05-18 — — WO disclosed
US-9115169-B2 Method of treating tumors LYTIX BIOPHARMA AS (NO) 2015-08-25 — — US disclosed
US-9109048-B2 Inhibition of tumor growth LYTIX BIOPHARMA AS (NO) 2015-08-18 — — US disclosed
US-20140037657-A1 INHIBITION OF TUMOR GROWTH LYTIX BIOPHARMA AS (NO) 2014-02-06 — — US disclosed
US-8283315-B2 Inhibition of tumour growth LYTIX BIOPHARMA AS (NO) 2012-10-09 — — US disclosed
US-20120108520-A1 Antimicrobial Compounds and Formulations LYTIX BIOPHARMA AS (NO) 2012-05-03 — — US disclosed
US-8143211-B2 Bioactive peptides LYTIX BIOPHARMA AS (NO) 2012-03-27 — — US disclosed
EP-1263471-B1 ANTIMICROBIAL COMPOUNDS AND FORMULATIONS LYTIX BIOPHARMA AS (NO) 2011-10-12 — — EP disclosed
EP-2338522-A1 Antitumoural therapies Lytix Biopharma AS (NO) 2011-06-29 — — EP disclosed
US-20100267621-A1 Antimicrobial Compounds and Formulations LYTIX BIOPHARMA AS (NO) 2010-10-21 — — US disclosed
US-20080287346-A1 Bioactive peptides SVENDSEN JOHN SIGURD 2008-11-20 — — US disclosed
US-20080019993-A1 Inhibition of tumour growth LYTIX BIOPHARMA AS (NO) 2008-01-24 — — US disclosed
US-7232803-B2 Antimicrobial compounds and formulations LYTIX BIOPHARMA AS (NO) 2007-06-19 — — US disclosed
US-6890902-B2 Cytotoxic modified lactoferrin peptides ALPHARMA AS (NO) 2005-05-10 — — US disclosed
US-20030195144-A1 Antimicrobial compounds and formulations LYTIX BIOPHARMA AS (NO) 2003-10-16 — — US disclosed
US-20030022821-A1 Bioactive peptides ALPHARMA AS 2003-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108520-A1 Antimicrobial Compounds and Formulations VIP, NONO, CLPTM1 SMN1; SMN2 4804/4885KDM4E 4599/4885TP53 3018/4885
US-20080287346-A1 Bioactive peptides VIP, NGLY1, IAPP SMN1; SMN2 3732/4885KDM4E 4285/4885TP53 42/4885
US-20100267621-A1 Antimicrobial Compounds and Formulations VIP, NONO, CLPTM1 SMN1; SMN2 4804/4885KDM4E 4599/4885TP53 3018/4885
US-20080019993-A1 Inhibition of tumour growth STING1, VIP, MIF SMN1; SMN2 4791/4885KDM4E 2793/4885TP53 9/4885
US-20030195144-A1 Antimicrobial compounds and formulations LPO, CLPTM1, VIP SMN1; SMN2 4829/4885KDM4E 4487/4885TP53 3368/4885
US-20030022821-A1 Bioactive peptides VIP, LITAF, LNPEP SMN1; SMN2 3706/4885KDM4E 4477/4885TP53 91/4885
US-20140037657-A1 INHIBITION OF TUMOR GROWTH STING1, VIP, MIF SMN1; SMN2 4847/4885KDM4E 2642/4885TP53 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.